TARS
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.85 · operating margin -16% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 12 500 titres (~979 125,00 $ US)
- Insiders
- LINK WILLIAM J PHD
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$979,125
Avg sell (VWAP, 90d window) $82.42 vs last close —
- Last activity
- 2026-09-15
- Last synced
-
2026-09-21 10:15:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-15 | LINK WILLIAM J PHD | Sell | 66 | $80.01 | $5,281 | Form 4 |
| 2026-09-04 | Lin Elizabeth Yeu | Sell | 5,386 | $90.00 | $484,740 | Form 4 |
| 2026-09-04 | Neervannan Seshadri | Sell | 4,564 | $85.00 | $387,940 | Form 4 |
| 2026-09-02 | Lin Elizabeth Yeu | Sell | 5,387 | $80.00 | $430,960 | Form 4 |
| 2026-09-01 | Lin Elizabeth Yeu | Sell | 4,601 | $73.86 | $339,830 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-17
TARS presents a mixed picture: while its liquidity score (75) reflects adequate near-term runway and narrowing losses, the weak fundamental trend score (45) underscores persistent negative cash flows and an unjustified…
The first sentence of the analysis written for TARS on 2026-09-17 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 93.2% | 93.0% | 90.9% | 96.3% | 96.4% | |
| Ebit Margin | -12.3% | -58.9% | -759.7% | -232.5% | -24.1% | |
| Ebitda Margin | -11.9% | -58.2% | -754.7% | -231.3% | -23.6% | |
| Operating Profit Margin | -15.7% | -65.9% | -820.5% | -242.9% | -21.3% | |
| Pretax Profit Margin | -14.3% | -63.2% | -778.9% | -240.5% | -24.1% | |
| Continuous Operations Profit Margin | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% | |
| Net Profit Margin | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% | |
| Bottom Line Profit Margin | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% | |
| Current Ratio | 3.853 | 4.425 | 6.934 | 14.607 | 15.329 | |
| Quick Ratio | 3.820 | 4.392 | 6.850 | 14.607 | 15.329 | |
| Solvency Ratio | -0.295 | -0.750 | -1.971 | -1.767 | -1.110 | |
| Cash Ratio | 1.353 | 1.176 | 6.090 | 4.645 | 14.927 | |
| Price To Earnings Ratio | -51.497 | -18.036 | -4.383 | -5.817 | -33.582 | |
| Price To Earnings Growth Ratio | 1.068 | 0.538 | -0.053 | -0.021 | 0.682 | |
| Forward Price To Earnings Growth Ratio | 1.068 | 0.538 | -0.053 | -0.021 | 0.682 | |
| Price To Earnings Diluted Ratio | -51.497 | -18.036 | -4.383 | -5.817 | -33.582 | |
| Price To Earnings Diluted Growth Ratio | 1.068 | 0.538 | -0.053 | -0.021 | 0.682 | |
| Price To Book Ratio | 9.962 | 9.273 | 3.021 | 1.871 | 2.774 | |
| Price To Sales Ratio | 7.580 | 11.381 | 34.104 | 13.981 | 8.110 | |
| Price To Free Cash Flow Ratio | -153.352 | -24.614 | -4.838 | -7.286 | 146.258 | |
| Price To Operating Cash Flow Ratio | -274.779 | -25.078 | -5.064 | -7.361 | 123.390 | |
| Debt To Assets Ratio | 0.167 | 0.192 | 0.114 | 0.089 | 0.011 | |
| Debt To Equity Ratio | 0.273 | 0.323 | 0.153 | 0.105 | 0.011 | |
| Debt To Capital Ratio | 0.214 | 0.244 | 0.133 | 0.095 | 0.011 | |
| Long Term Debt To Capital Ratio | 0.195 | 0.242 | 0.131 | 0.092 | 0.000 | |
| Financial Leverage Ratio | 1.637 | 1.679 | 1.348 | 1.181 | 1.073 | |
| Working Capital Turnover Ratio | 1.361 | 0.739 | 0.081 | 0.138 | 0.346 | |
| Operating Cash Flow Ratio | -0.092 | -1.030 | -3.181 | -3.178 | 0.327 | |
| Operating Cash Flow Sales Ratio | -0.028 | -0.454 | -6.734 | -1.899 | 0.066 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.792 | 1.019 | 1.047 | 1.010 | 0.844 | |
| Debt Service Coverage Ratio | -6.230 | -14.298 | -40.828 | -28.925 | 0.000 | |
| Interest Coverage Ratio | -7.943 | -16.190 | -44.390 | -30.384 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.133 | -1.146 | -3.888 | -2.426 | 1.982 | |
| Capital Expenditure Coverage Ratio | -1.263 | -52.985 | -21.355 | -96.897 | 6.396 | |
| Dividend Paid And Capex Coverage Ratio | -1.263 | -52.985 | -21.355 | -96.897 | 6.396 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -62.141 | -19.344 | -3.040 | -5.183 | -21.770 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 93.2% | ▲0.2% | ▼-0.7% |
| Ebit Margin | -12.3% | ▲46.6% | ▲205.2% |
| Ebitda Margin | -11.9% | ▲46.3% | ▲204.1% |
| Operating Profit Margin | -15.7% | ▲50.2% | ▲217.6% |
| Pretax Profit Margin | -14.3% | ▲48.9% | ▲209.9% |
| Continuous Operations Profit Margin | -14.7% | ▲48.4% | ▲209.6% |
| Net Profit Margin | -14.7% | ▲48.4% | ▲209.6% |
| Bottom Line Profit Margin | -14.7% | ▲48.4% | ▲209.6% |
| Current Ratio | 3.853 | ▼-0.572 | ▼-5.177 |
| Quick Ratio | 3.820 | ▼-0.572 | ▼-5.180 |
| Solvency Ratio | -0.295 | ▲0.455 | ▲0.883 |
| Cash Ratio | 1.353 | ▲0.177 | ▼-4.285 |
| Price To Earnings Ratio | -51.497 | ▼-33.461 | ▼-28.834 |
| Price To Earnings Growth Ratio | 1.068 | ▲0.531 | ▲0.625 |
| Forward Price To Earnings Growth Ratio | 1.068 | ▲0.531 | ▲0.625 |
| Price To Earnings Diluted Ratio | -51.497 | ▼-33.461 | ▼-28.834 |
| Price To Earnings Diluted Growth Ratio | 1.068 | ▲0.531 | ▲0.625 |
| Price To Book Ratio | 9.962 | ▲0.689 | ▲4.582 |
| Price To Sales Ratio | 7.580 | ▼-3.801 | ▼-7.451 |
| Price To Free Cash Flow Ratio | -153.352 | ▼-128.738 | ▼-144.585 |
| Price To Operating Cash Flow Ratio | -274.779 | ▼-249.701 | ▼-237.001 |
| Debt To Assets Ratio | 0.167 | ▼-0.026 | ▲0.052 |
| Debt To Equity Ratio | 0.273 | ▼-0.050 | ▲0.100 |
| Debt To Capital Ratio | 0.214 | ▼-0.030 | ▲0.075 |
| Long Term Debt To Capital Ratio | 0.195 | ▼-0.048 | ▲0.063 |
| Financial Leverage Ratio | 1.637 | ▼-0.042 | ▲0.253 |
| Working Capital Turnover Ratio | 1.361 | ▲0.622 | ▲0.828 |
| Operating Cash Flow Ratio | -0.092 | ▲0.938 | ▲1.339 |
| Operating Cash Flow Sales Ratio | -0.028 | ▲0.426 | ▲1.782 |
| Free Cash Flow Operating Cash Flow Ratio | 1.792 | ▲0.773 | ▲0.649 |
| Debt Service Coverage Ratio | -6.230 | ▲8.068 | ▲11.826 |
| Interest Coverage Ratio | -7.943 | ▲8.248 | ▲11.839 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.133 | ▲1.013 | ▲0.989 |
| Capital Expenditure Coverage Ratio | -1.263 | ▲51.722 | ▲31.958 |
| Dividend Paid And Capex Coverage Ratio | -1.263 | ▲51.722 | ▲31.958 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -62.141 | ▼-42.797 | ▼-39.845 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.42B | $2.08B | $595.0M | $360.9M | $462.5M | |
| Enterprise value | $3.33B | $2.06B | $400.3M | $309.5M | $293.0M | |
| EV / Sales | 7.38x | 11.26x | 22.94x | 11.99x | 5.14x | |
| EV / Op. cash flow | -267.55x | -24.81x | -3.41x | -6.31x | 78.18x | |
| EV / Free cash flow | -149.32x | -24.35x | -3.25x | -6.25x | 92.67x | |
| EV / EBITDA | -62.14x | -19.34x | -3.04x | -5.18x | -21.77x | |
| Net debt / EBITDA | 1.68x | 0.21x | 1.48x | 0.86x | 12.59x | |
| Current ratio | 3.85x | 4.42x | 6.93x | 14.61x | 15.33x | |
| Income quality | 0.19x | 0.72x | 0.86x | 0.79x | -0.27x | |
| Graham net-net | $6 | $5 | $6 | $8 | $8 | |
| Tax burden | 103.2% | 100.0% | 100.0% | 100.0% | 100.4% | |
| Interest burden | 116.1% | 107.3% | 102.5% | 103.4% | 100.0% | |
| Working capital | $387.1M | $276.1M | $219.2M | $209.9M | $164.5M | |
| Invested capital | $416.2M | $287.3M | $226.4M | $211.5M | $166.3M | |
| Return on assets | -11.8% | -30.7% | -51.2% | -27.2% | -7.7% | |
| Operating ROA | -15.1% | -37.5% | -58.0% | -30.8% | -6.9% | |
| Return on tangible assets | -12.0% | -31.3% | -51.9% | -27.2% | -7.7% | |
| Return on equity | -19.3% | -51.5% | -69.0% | -32.2% | -8.3% | |
| Return on invested capital | -16.6% | -40.6% | -62.5% | -29.4% | -7.2% | |
| Return on capital employed | -16.6% | -40.7% | -62.6% | -29.5% | -7.3% | |
| Earnings yield | -1.9% | -5.5% | -22.8% | -17.2% | -3.0% | |
| Free cash flow yield | -0.7% | -4.1% | -20.7% | -13.7% | 0.7% | |
| Capex / Op. cash flow | -79.2% | -1.9% | -4.7% | -1.0% | 15.6% | |
| Capex / Depreciation | 542.9% | 127.9% | 627.4% | 155.7% | 187.8% | |
| Capex / Sales | 2.2% | 0.9% | 31.5% | 2.0% | 1.0% | |
| SG&A / Sales | 94.7% | 129.7% | 623.0% | 174.1% | 44.5% | |
| R&D / Sales | 14.3% | 29.2% | 288.4% | 165.1% | 73.1% | |
| Stock comp / Sales | 9.2% | 15.2% | 113.7% | 52.1% | 14.8% | |
| Intangibles / Total assets | 1.3% | 2.2% | 1.5% | 0.0% | 0.0% | |
| Days sales outstanding | 70d | 96d | 371d | 51d | 1d | |
| Days payables outstanding | 195d | 789d | 4072d | 2101d | 502d | |
| Operating cycle | 122d | 170d | 1082d | 51d | 1d | |
| Cash conversion cycle | -72d | -619d | -2990d | -2051d | -502d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+64.3%EV / Sales ▼-34.4%EV / EBITDA ▼-221.2%EV / Op. cash flow ▼-242.742Earnings yield ▲+0.036
Profitability
Return on equity ▲+0.321Return on assets ▲+0.188Return on invested capital ▲+0.240Return on capital employed ▲+0.240Operating ROA ▲+0.224Income quality ▼-0.531Tax burden ▲+0.032
Efficiency
Days sales outstanding ▼-25.438Days payables outstanding ▼-594.461Operating cycle ▼-47.990Cash conversion cycle ▲+546.470Capex / Sales ▲+0.013R&D / Sales ▼-0.149
Balance-sheet strength
Current ratio ▼-0.572Net debt / EBITDA ▲+1.469Working capital ▲+110994000.000Invested capital ▲+128913000.000Intangibles / Total assets ▼-0.009
Change over 5 years
Valuation
Market cap ▲+639.8%EV / Sales ▲+43.6%EV / EBITDA ▼-185.4%EV / Op. cash flow ▼-345.732Earnings yield ▲+0.010
Profitability
Return on equity ▼-0.110Return on assets ▼-0.041Return on invested capital ▼-0.094Return on capital employed ▼-0.094Operating ROA ▼-0.082Income quality ▲+0.459Tax burden ▲+0.028
Efficiency
Days sales outstanding ▲+69.853Days payables outstanding ▼-307.450Operating cycle ▲+121.860Cash conversion cycle ▲+429.310Capex / Sales ▲+0.012R&D / Sales ▼-0.589
Balance-sheet strength
Current ratio ▼-11.477Net debt / EBITDA ▼-10.910Working capital ▲+222613000.000Invested capital ▲+249895000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-04 Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt''s disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus'' differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company.
- 2026-09-04 114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp Bank of New York Mellon Corp bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 114,458 shares of the company''s stock, valued at approximately $7,204,000. Bank of New York Mellon
- 2026-09-03 Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group. Gildeuretinol was well tolerated with no patient-reported events of dark adaptation delays or night blindness.
- 2026-09-01 Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th H.C.
- 2026-08-24 Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug Designation for oral gildeuretinol for the treatment of Stargardt disease.
- 2026-08-07 Tarsus Pharmaceuticals Q2 Earnings Call Highlights Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol, also known as ALK-001, to its pipeline.
- 2026-08-06 Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
- 2026-08-06 Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.48 per share a year ago.
- 2026-08-06 Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year
- 2026-08-06 Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $125.0 million, before deducting placement agent fees and other private placement expenses.